An Emerging Role of mTOR in Lipid Biosynthesis

Lipid biosynthesis is essential for the maintenance of cellular homeostasis. The lipids produced by cells (glycerolipids, fatty acids, phospholipids, cholesterol, and sphingolipids) are used as an energy source/reserve, as building blocks for membrane biosynthesis, as precursor molecules for the synthesis of various cellular products, and as signaling molecules. Defects in lipid synthesis or processing contribute to the development of many diseases, including obesity, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer. Studies published over the last few years have shown that the target of rapamycin (TOR), a conserved serine/threonine kinase with an important role in regulating cell growth, controls lipid biosynthesis through various mechanisms. Here, we review these findings and briefly discuss their potential relevance for human health and disease.

[1]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[2]  A. Sorisky,et al.  Rapamycin‐sensitive phase of 3T3‐L1 preadipocyte differentiation after clonal expansion , 2001, Journal of cellular physiology.

[3]  L. Cantley,et al.  Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. , 2009, The Biochemical journal.

[4]  A. Sorisky,et al.  Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1 , 2004, International Journal of Obesity.

[5]  Min-young Lee,et al.  Lipin1 Is a Key Factor for the Maturation and Maintenance of Adipocytes in the Regulatory Network with CCAAT/Enhancer-binding Protein α and Peroxisome Proliferator-activated Receptor γ2* , 2008, Journal of Biological Chemistry.

[6]  S. Caldwell,et al.  Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.

[7]  Claudio R. Santos,et al.  SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth , 2008, Cell metabolism.

[8]  F. Lang,et al.  (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. , 2006, Physiological reviews.

[9]  Ted Powers,et al.  Regulation of ceramide biosynthesis by TOR complex 2. , 2008, Cell metabolism.

[10]  S. Kersten.  Mechanisms of nutritional and hormonal regulation of lipogenesis , 2001, EMBO reports.

[11]  G. Ruvkun,et al.  Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. , 2009, Genes & development.

[12]  B. Spiegelman,et al.  ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Julian Downward,et al.  PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP , 2005, Oncogene.

[14]  C. Mounier,et al.  Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver , 2007, Journal of Cell Communication and Signaling.

[15]  N. Sonenberg,et al.  Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. , 2007, The Journal of clinical investigation.

[16]  F. Foufelle,et al.  Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[18]  J. Auwerx,et al.  Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.

[19]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[20]  G. Steinberg,et al.  Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.

[21]  D. Alessi,et al.  New Insights into mTOR Signaling: mTORC2 and Beyond , 2009, Science Signaling.

[22]  A. Sorisky,et al.  Rapamycin inhibits human adipocyte differentiation in primary culture. , 2000, Obesity research.

[23]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[24]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[25]  W. Yeh,et al.  Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Yandell,et al.  Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Reue,et al.  Lipin Expression Preceding Peroxisome Proliferator-activated Receptor-γ Is Critical for Adipogenesis in Vivo and in Vitro* , 2004, Journal of Biological Chemistry.

[28]  F. Foufelle,et al.  SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective , 2007, Hormone Research in Paediatrics.

[29]  D. Pearce,et al.  Rictor/TORC2 Regulates Caenorhabditis elegans Fat Storage, Body Size, and Development through sgk-1 , 2009, PLoS biology.

[30]  Jiyoung Park,et al.  Regulation of adipocyte differentiation and insulin action with rapamycin. , 2004, Biochemical and biophysical research communications.

[31]  Jie Chen,et al.  regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. , 2004, Diabetes.

[32]  T. Golub,et al.  The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation , 2002, Molecular and Cellular Biology.

[33]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[34]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[35]  Jing Ye,et al.  Up-Regulation of Mitochondrial Activity and Acquirement of Brown Adipose Tissue-Like Property in the White Adipose Tissue of Fsp27 Deficient Mice , 2008, PloS one.

[36]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[37]  O. MacDougald,et al.  Adipocyte differentiation from the inside out , 2006, Nature Reviews Molecular Cell Biology.

[38]  G. Perdomo,et al.  The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. , 2007, Metabolism: clinical and experimental.

[39]  J. Auwerx,et al.  mTOR complex 2 in adipose tissue negatively controls whole-body growth , 2009, Proceedings of the National Academy of Sciences.

[40]  J. Lawrence,et al.  Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[42]  A. Marette,et al.  Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. , 2005, Endocrinology.

[43]  B. Spiegelman,et al.  ADD1/SREBP1 activates PPARγ through the production of endogenous ligand , 1998 .

[44]  Chin-Lee Wu,et al.  Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway , 2009, PloS one.

[45]  Claudio R. Santos,et al.  A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. , 2009, Biochemical Society transactions.

[46]  S. Wakil,et al.  Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[48]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.